31.24
+0.005(+0.02%)
Currency In USD
Address
830 Winter Street
Waltham, MA 02451-1477
United States of America
Phone
781 895 0600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
277
First IPO Date
November 17, 1989
| Name | Title | Pay | Year Born |
| Mr. Mark Joseph Enyedy | President, Chief Executive Officer & Director | 1.28M | 1964 |
| Dr. Michael J. Vasconcelles M.D., Ph.D. | Chief Medical Officer | 304,620 | 1963 |
| Dr. Theresa G. Wingrove | Senior Vice President of Regulatory Affairs & Quality | 548,205 | 1958 |
| Mr. Daniel S. Char J.D. | Senior Vice President, Chief Legal Officer & Secretary | 0 | 1962 |
| Ms. Audrey Bergan | Senior Vice President & Chief HR Officer | 0 | N/A |
| Ms. Courtney O'Konek | Senior Director of Corporate Communications & Investor Relations | 0 | N/A |
| Ms. Lauren A. White M.B.A. | Senior Vice President & Chief Financial Officer | 0 | 1979 |
| Ms. Isabel Kalofonos | Senior Vice President & Chief Commercial Officer | 0 | N/A |
| Anabel Chan | Head of Investor Relations | 0 | N/A |
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.